Pharmaron continues buybacks of series 2 convertibles from open market

Chicago, Jan. 16 – Pharmaron Beijing Co. Ltd. announced another partial repurchase and cancellation regarding its RMB 1.916 billion zero-coupon dollar-settled series 2 convertible bonds due 2026 in a notice.

The company has been buying back its convertible notes from the open market.

As of Jan. 15, the company bought another RMB 160 million of the bonds, bringing the total amount repurchased to RMB 865 million, or 45.1% of the original principal amount.

After cancellation, which is expected as soon as possible, there will be RMB 1.051 billion of the notes outstanding.

Pharmaron is a Beijing-based research and development service provider for the life sciences industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.